Clomiphene


Triphenylethylene SERM (mixed isomers)

A racemic mixture of enclomiphene (anti-estrogen) and zuclomiphene (estrogen agonist); the prototype ovulation-inducing agent.

Abstract

Clomiphene (2-[4-[(E/Z)-2-chloro-1,2-diphenylvinyl]phenoxy]-N,N-diethylethanamine; CAS 911-45-5; molecular formula C26H28ClNO; molecular weight 405.96) is a triphenylethylene SERM developed at Merrell and approved by the FDA in 1967 under the trade name Clomid. The compound is sold as a racemic mixture of approximately 38 percent zuclomiphene ((Z)-isomer, an ER agonist) and 62 percent enclomiphene ((E)-isomer, an ER antagonist). The therapeutic effect in ovulation induction is driven primarily by enclomiphene-mediated antagonism of hypothalamic ER, releasing the negative feedback on GnRH and consequently increasing pituitary FSH and LH; the resulting follicular development drives ovulation. The zuclomiphene component is approximately 5-fold longer half-life than enclomiphene (zuclomiphene t1/2 approximately 30 days, enclomiphene t1/2 approximately 30 hours), causing the agonist component to dominate at later cycles and produce some unwanted estrogen-like effects (cervical mucus changes, antiestrogen rebound). Approved for ovulation induction in anovulatory women. Off-label use in male hypogonadism (induces endogenous testosterone via the same FSH/LH route) is common. Used as the canonical triphenylethylene SERM with HPG-stimulating activity.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph